Putin claims Russia has developed the first coronavirus vaccineAug. 11, 2020 5:24 AM ET|About: Pfizer Inc. (PFE)|By: Yoel Minkoff, SA News Editor https://seekingalpha.com/news/3603880-putin-claims-russia-developed-first-coronavirus-vaccine
Sorrento adds to COVID-19-stoked rally, shares up 24% Aug. 10, 2020 1:56 PM ET|About: Sorrento Therapeutics,... (SRNE)|By: Douglas W. House, SA News Editor Sorrento Therapeutics (SRNE +23.6%) is adding to its recent breakout on almost double normal volume. Shares have jumped 159% since Wednesday, July 24, when it announced that it planned to acquire COVID-19 therapy developer SmartPharm Therapeutics. The following Monday, July 29, it announced that it in-licensed rights to a rapid test that detects the presence of the SARS-CoV-2 virus in saliva in as little as 30 minutes.On Friday, May 15, shares rocketed 158% after the company announced a "cure" for COVID-19. Shares quickly retraced on questions about the veracity of its claim, bottoming at $3.82 on June 4. Investors appeared to have brushed off such concerns since shares are up five-fold since then.Chairman, CEO and President Henry Li, Ph.D. is, no doubt, pleased with the share appreciation. Last week, the board authorized a 10-year performance award for him based solely on the market cap of the company. He will earn options to purchase up to ~24.9M shares at $17.30 representing a 10% stake in the company if fully exercised. The award vests in 10 equal tranches starting with ~2.5M options if the company's market cap reaches $5B. The 10th and last tranche vests if the company's value hits $35B. Assuming full vestment and no further equity offerings, his total award will be potentially worth ~$3.3B. https://seekingalpha.com/news/3603544-sorrento-adds-to-covidminus-19-stoked-rally-shares-up-24?utm_medium=email&utm_source=seeking_alpha&mail_subject=srne-sorrento-adds-to-covid-19-stoked-rally-shares-up-24&utm_campaign=rta-stock-news&utm_content=link-3
Pfizer to manufacture COVID-19 med remdesivirAug. 7, 2020 8:10 AM ET|About: Pfizer Inc. (PFE)|By: Douglas W. House, SA News Editor https://seekingalpha.com/news/3602826-pfizer-to-manufacture-covidminus-19-med-remdesivir?utm_medium=email&utm_source=seeking_alpha&mail_subject=gild-pfe-pfizer-to-manufacture-covid-19-med-remdesivir&utm_campaign=rta-stock-news&utm_content=link-3
Alguna experiencia por aqui, con este indicador ?Fibonacci Time ZonesWhat are Fibonacci Time Zones?KEY TAKEAWAYSFibonacci time zones are vertical lines that represent potential areas where a swing high, low, or reversal could occur.Fibonacci time zones may not indicate exact reversal points. They are time-based areas to be aware of.Fibonacci time zones only indicate potential areas of importance related to time. No regard is given to price. The zone could mark a minor high or low, or a significant high or low.Fibonacci time zones are based on the Fibonacci number sequence which gives us the Golden Ratio. The ratio is found throughout nature and architecture.https://www.investopedia.com/terms/f/fibonaccitimezones.asp#:~:text=Fibonacci%20time%20zones%20are%20a,high%2C%20low%2C%20or%20reversal.
TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program in Purchase Agreement for up to $250 million in Milestone Payments plus Royalties on Future Net Sales https://investors.dynavax.com/news-releases/news-release-details/trisalus-life-sciences-acquires-dynavaxs-sd-101-oncology-program
Pricing Covid-19 vaccines too high could backfire on big pharmaceutical companies.. I don’t want to single out Moderna here. It doesn’t have a single successful commercial drug, nor any other Phase 3 candidates; its need to make money off this vaccine is arguably acute. Larger drug companies are different. Yet Pfizer NSE 2.30% Inc.’s CEO recently said that calls for companies not to consider making a profit on their Covid-19 vaccines were “fanatic and radical.” (AstraZeneca NSE 1.51% PLC and Johnson & Johnson have promised a not-for-profit effort on their Covid-19 vaccines, Read more at:https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/pricing-covid-19-vaccines-too-high-could-backfire-on-big-pharmaceutical-companies/articleshow/77325474.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst ..
Moderna CMO vende acciones cuando comienzan los ensayos finales de vacunas, lo que genera preocupaciónEl CEO Stéphane Bancel también ha cobrado acciones en los últimos meses.Por JERUSALÉN POST STAFF 2 DE AGOSTO DE 2020 04:36 https://www.jpost.com/international/moderna-cmo-sells-shares-as-final-vaccine-trials-begin-raising-concerns-637166
Inovio Pharmaceuticals: A Focus On The HPV Pipeline Candidates SummaryCOVID vaccine INO-4800 is just one piece of the Inovio (INO) puzzle.Addressing the Human Papilloma Virus remains a high priority for Inovio.Results from the PHI and PHII VGX3100 trials are promising in the fight against HPV types 16 and 18.INO-3107 is granted "Orphan Drug Designation" by the US Food and Drug Administration. Is there more to follow? https://seekingalpha.com/article/4363675-inovio-pharmaceuticals-focus-on-hpv-pipeline-candidates?utm_medium=email&utm_source=seeking_alpha&mail_subject=ino-inovio-pharmaceuticals-a-focus-on-the-hpv-pipeline-candidates&utm_campaign=rta-stock-article&utm_content=link-2